While SGLT2-i were initially approved for a primary indication of diabetes, landmark trials followed (including EMPEROR-Reduced and EMPEROR-Preserved) that demonstrated significant cardiovascular benefits regardless of the presence or absence of diabetes in individuals with heart failure with reduced as well as preserved ejection fraction [16, 17]. This evidence concerns the gene SLC5A2 and heart failure.